Tag: capital

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.

Following the capital increase of €15 million (including the share premium) through an accelerated book building process (ABB) on 10 June 2026, 311,203 new shares are being issued today (12 June 2026).

EUROCASTLE INVESTMENT LIMITED

GEORGE TOWN, Cayman Islands, June 12, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today upgrades its copy trading platform, expanding its zero-slippage capability.

CALGARY, Alberta, June 11, 2026 (GLOBE NEWSWIRE) -- Veteran Capital Corp. ("Veteran") (TSXV: VCC.P), a Capital Pool Company listed on the TSX Venture Exchange (the "Exchange"), announces that it has terminated its letter of intent with Powerhive, Inc. ("Powerhive") for its proposed Qualifying Transaction as a result of Powerhive’s failure to complete its required financing and/or enter into a binding definitive agreement within the timeframes set out in the letter of intent, despite repeated extensions.

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index^® (NDX^®), which will become effective prior to market open on Monday, June 22, 2026.

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options in a private placement priced at-the-market under Nasdaq rules.